[8-K] Aquestive Therapeutics, Inc. Reports Material Event
Aquestive Therapeutics announced a press release reporting its reported financial results for the second quarter ended June 30, 2025 and provided a business update. The press release and accompanying financial schedules are included as Exhibit 99.1 and are referenced in Item 2.02 of the Current Report.
The company also furnished investor presentations and a corporate presentation as Exhibits 99.2 and 99.3, stating those materials are available on the Events and Presentations page of its website. The filing clarifies that the disclosed materials are furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act.
Aquestive Therapeutics ha pubblicato un comunicato stampa che riporta i risultati finanziari per il secondo trimestre chiuso il June 30, 2025 e ha fornito un aggiornamento aziendale. Il comunicato e i prospetti finanziari allegati sono inclusi come Exhibit 99.1 e sono richiamati nell'Elemento 2.02 del Current Report.
L'azienda ha inoltre reso disponibili presentazioni per investitori e una presentazione aziendale come Exhibits 99.2 and 99.3, indicando che tali materiali sono consultabili nella pagina Eventi e Presentazioni del suo sito web. Il deposito chiarisce che i materiali divulgati sono forniti e non devono essere considerati 'filed' ai fini della Sezione 18 del Exchange Act.
Aquestive Therapeutics anunció un comunicado de prensa con sus resultados financieros del segundo trimestre finalizado el June 30, 2025 y ofreció una actualización sobre el negocio. El comunicado y los estados financieros adjuntos se incluyen como Exhibit 99.1 y se citan en el Punto 2.02 del Current Report.
La compañía también facilitó presentaciones para inversores y una presentación corporativa como Exhibits 99.2 and 99.3, indicando que esos materiales están disponibles en la sección Eventos y Presentaciones de su sitio web. El documento aclara que los materiales divulgados son suministrados y no deben considerarse 'filed' a los efectos de la Sección 18 del Exchange Act.
Aquestive Therapeutics는 2025년 6월 30일로 종료된 2분기 재무실적을 발표하는 보도자료를 공개하고 사업 현황을 업데이트했습니다. 보도자료와 첨부 재무자료는 Exhibit 99.1로 포함되어 있으며 Current Report의 항목 2.02에서 참조됩니다.
회사는 또한 투자자용 프레젠테이션과 기업 프레젠테이션을 Exhibits 99.2 and 99.3으로 제공했으며, 해당 자료들이 자사 웹사이트의 이벤트 및 프레젠테이션 페이지에서 확인할 수 있다고 밝혔습니다. 이 신고서는 공개된 자료들이 제공된(furnished) 것으로서 Exchange Act의 Section 18 목적상 'filed'로 간주되어서는 안 된다고 명시합니다.
Aquestive Therapeutics a publié un communiqué de presse présentant ses résultats financiers pour le deuxième trimestre clos le June 30, 2025 et a fourni une mise à jour sur ses activités. Le communiqué et les tableaux financiers annexes sont inclus en tant que Exhibit 99.1 et sont mentionnés à l'article 2.02 du Current Report.
La société a également transmis des présentations aux investisseurs et une présentation corporate en tant que Exhibits 99.2 and 99.3, indiquant que ces documents sont disponibles sur la page Événements et Présentations de son site web. Le dépôt précise que les documents divulgués sont remis et ne doivent pas être considérés comme 'filed' au sens de la Section 18 du Exchange Act.
Aquestive Therapeutics gab eine Pressemitteilung bekannt, in der die gemeldeten Finanzergebnisse für das am June 30, 2025 beendete zweite Quartal dargestellt werden, und gab ein Geschäfts-Update. Die Pressemitteilung und die beigefügten Finanzunterlagen sind als Exhibit 99.1 enthalten und werden in Punkt 2.02 des Current Report genannt.
Das Unternehmen hat außerdem Investorenpräsentationen und eine Unternehmenspräsentation als Exhibits 99.2 and 99.3 bereitgestellt und erklärt, dass diese Unterlagen auf der Seite Events and Presentations seiner Website verfügbar sind. Die Meldung stellt klar, dass die offengelegten Materialien bereitgestellt wurden und nicht als 'filed' im Sinne von Abschnitt 18 des Exchange Act zu betrachten sind.
- None.
- None.
Insights
TL;DR: Routine earnings disclosure and investor materials were furnished; the 8-K contains no numerical results within the filing text itself.
The filing serves to furnish a press release reporting the company's financial results for the quarter ended June 30, 2025, and to provide investor presentation materials. This is a standard disclosure step to make earnings and supplemental slides available to investors and analysts. The 8-K notes the materials are furnished, not filed, limiting certain legal liabilities. Investors will need to review Exhibit 99.1 and the supplemental materials for actual financial metrics because the 8-K text does not include numerical results or schedules in-line.
TL;DR: Disclosure is procedural and transparent; designation of materials as "furnished" follows common SEC practice.
The company furnished its earnings press release and investor presentations as exhibits, and explicitly stated those exhibits are not "filed" under the Exchange Act for Section 18 liability. This distinction is customary and indicates the company is providing information under Regulation FD and Form 8-K requirements. The filing also confirms presentation availability on the company website, subject to discontinuation at the company's discretion. No governance or control changes are disclosed here.
Aquestive Therapeutics ha pubblicato un comunicato stampa che riporta i risultati finanziari per il secondo trimestre chiuso il June 30, 2025 e ha fornito un aggiornamento aziendale. Il comunicato e i prospetti finanziari allegati sono inclusi come Exhibit 99.1 e sono richiamati nell'Elemento 2.02 del Current Report.
L'azienda ha inoltre reso disponibili presentazioni per investitori e una presentazione aziendale come Exhibits 99.2 and 99.3, indicando che tali materiali sono consultabili nella pagina Eventi e Presentazioni del suo sito web. Il deposito chiarisce che i materiali divulgati sono forniti e non devono essere considerati 'filed' ai fini della Sezione 18 del Exchange Act.
Aquestive Therapeutics anunció un comunicado de prensa con sus resultados financieros del segundo trimestre finalizado el June 30, 2025 y ofreció una actualización sobre el negocio. El comunicado y los estados financieros adjuntos se incluyen como Exhibit 99.1 y se citan en el Punto 2.02 del Current Report.
La compañía también facilitó presentaciones para inversores y una presentación corporativa como Exhibits 99.2 and 99.3, indicando que esos materiales están disponibles en la sección Eventos y Presentaciones de su sitio web. El documento aclara que los materiales divulgados son suministrados y no deben considerarse 'filed' a los efectos de la Sección 18 del Exchange Act.
Aquestive Therapeutics는 2025년 6월 30일로 종료된 2분기 재무실적을 발표하는 보도자료를 공개하고 사업 현황을 업데이트했습니다. 보도자료와 첨부 재무자료는 Exhibit 99.1로 포함되어 있으며 Current Report의 항목 2.02에서 참조됩니다.
회사는 또한 투자자용 프레젠테이션과 기업 프레젠테이션을 Exhibits 99.2 and 99.3으로 제공했으며, 해당 자료들이 자사 웹사이트의 이벤트 및 프레젠테이션 페이지에서 확인할 수 있다고 밝혔습니다. 이 신고서는 공개된 자료들이 제공된(furnished) 것으로서 Exchange Act의 Section 18 목적상 'filed'로 간주되어서는 안 된다고 명시합니다.
Aquestive Therapeutics a publié un communiqué de presse présentant ses résultats financiers pour le deuxième trimestre clos le June 30, 2025 et a fourni une mise à jour sur ses activités. Le communiqué et les tableaux financiers annexes sont inclus en tant que Exhibit 99.1 et sont mentionnés à l'article 2.02 du Current Report.
La société a également transmis des présentations aux investisseurs et une présentation corporate en tant que Exhibits 99.2 and 99.3, indiquant que ces documents sont disponibles sur la page Événements et Présentations de son site web. Le dépôt précise que les documents divulgués sont remis et ne doivent pas être considérés comme 'filed' au sens de la Section 18 du Exchange Act.
Aquestive Therapeutics gab eine Pressemitteilung bekannt, in der die gemeldeten Finanzergebnisse für das am June 30, 2025 beendete zweite Quartal dargestellt werden, und gab ein Geschäfts-Update. Die Pressemitteilung und die beigefügten Finanzunterlagen sind als Exhibit 99.1 enthalten und werden in Punkt 2.02 des Current Report genannt.
Das Unternehmen hat außerdem Investorenpräsentationen und eine Unternehmenspräsentation als Exhibits 99.2 and 99.3 bereitgestellt und erklärt, dass diese Unterlagen auf der Seite Events and Presentations seiner Website verfügbar sind. Die Meldung stellt klar, dass die offengelegten Materialien bereitgestellt wurden und nicht als 'filed' im Sinne von Abschnitt 18 des Exchange Act zu betrachten sind.
